Prostaglandin I2 analogues enhance already exuberant Th17 cell responses in systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 71, Issue 12, 2012, Pages 2044-2050

  Truchetet, Marie Elise ^a   Allanore, Yannick ^b   Montanari, Elisa ^a   Chizzolini, Carlo ^a   Brembilla, Nicolò Costantino ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b INSTITUT COCHIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; CD4 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOKINE ANTIBODY; GAMMA INTERFERON; ILOPROST; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 4; PROSTACYCLIN RECEPTOR; TREPROSTINIL;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; FINGER ULCER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE COUNT; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; TH17 CELL;

ADAPTIVE IMMUNITY; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; EPOPROSTENOL; FEMALE; HUMANS; ILOPROST; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKINS; MALE; MIDDLE AGED; MONOCYTES; PLATELET AGGREGATION INHIBITORS; SCLERODERMA, SYSTEMIC; TH1 CELLS; TH17 CELLS; YOUNG ADULT;

EID: 84868506645     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201400     Document Type: Article

References (51)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.
2. Chizzolini C, Brembilla NC, Montanari E, et al. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 2011;10:276-81.
3. Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther 2009;11:257.
4. Salmon-Ehr V, Serpier H, Nawrocki B, et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 1996;132:802-6.
5. Scaletti C, Vultaggio A, Bonifacio S, et al. Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthritis Rheum 2002;46:445-50.
6. Parel Y, Aurrand-Lions M, Scheja A, et al. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 2007;56:3459-67.
7. Fuschiotti P, Medsger TA Jr., Morel PA. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 2009;60:1119-28.
8. Medsger TA Jr., Ivanco DE, Kardava L, et al. GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum 2011;63:1738-47.
9. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
10. Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009;4:e5903.
11. Meloni F, Solari N, Cavagna L, et al. Frequency of Th1, Th2 and Th17 producing T lymphocytes in bronchoalveolar lavage of patients with systemic sclerosis. Clin Exp Rheumatol 2009;27:765-72.
12. Fenoglio D, Battaglia F, Parodi A, et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol 2011;139:249-57.
13. Truchetet ME, Brembilla NC, Montanari E, et al. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 2011;13:R166.
14. Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000;43:2455-63.
15. Murata M, Fujimoto M, Matsushita T, et al. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008;50:240-2.
16. Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-14.
17. Stratton R, Shiwen X, Martini G, et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108:241-50.
18. Kawald A, Burmester GR, Huscher D, et al. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol 2008;35:1830-7.
19. Scorza R, Caronni M, Mascagni B, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001;19:503-8.
20. Hung CH, Chu YT, Suen JL, et al. Regulation of cytokine expression in human plasmacytoid dendritic cells by prostaglandin I2 analogues. Eur Respir J 2009;33:405-10.
21. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000;1483:285-93.
22. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-226.
23. Lai YJ, Pullamsetti SS, Dony E, et al. Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. Am J Respir Crit Care Med 2008;178:188-96.
24. Della Bella S, Molteni M, Mocellin C, et al. Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat 2001;65:73-83.
25. D'Amelio P, Cristofaro MA, D'Amico L, et al. Iloprost modulates the immune response in systemic sclerosis. BMC Immunol 2010;11:62.
26. Jorres A, Dinter H, Topley N, et al. Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. Cytokine 1997;9:119-25.
27. Czeslick EG, Simm A, Grond S, et al. Inhibition of intracellular tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest 2003;33:1013-17.
28. Wang WL, Kuo CH, Chu YT, et al. Prostaglandin I (2) analogues suppress TNF-alpha expression in human monocytes via mitogen-activated protein kinase pathway. Inflamm Res 2011;60:655-63.
29. Muller T, Durk T, Blumenthal B, et al. Iloprost has potent anti-inflammatory properties on human monocyte-derived dendritic cells. Clin Exp Allergy 2010;40:1214-21.
30. Yeh CH, Kuo CH, Yang SN, et al. Prostaglandin I2 analogs suppress tumor necrosis factor alpha production and the maturation of human monocyte-derived dendritic cells. J Investig Med 2011;59:1109-15.
31. Zhu Y, Liu Y, Zhou W, et al. A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir Res 2010;11:34.
32. Zhou W, Blackwell TS, Goleniewska K, et al. Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells. J Leukoc Biol 2007;81:809-17.
33. Jaffar Z, Ferrini ME, Shaw PK, et al. Prostaglandin I (2) promotes the development of IL-17-producing gammadelta T cells that associate with the epithelium during allergic lung inflammation. J Immunol 2011;187:5380-91.
34. Li H, Bradbury JA, Dackor RT, et al. Cyclooxygenase-2 regulates Th17 cell differentiation during allergic lung inflammation. Am J Respir Crit Care Med 2011;184:37-49.
35. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
36. Chizzolini C, Rezzonico R, De Luca C, et al. Th2 cell membrane factors in association with IL-4 enhance matrix metalloproteinase-1 (MMP-1) while decreasing MMP-9 production by granulocyte-macrophage colony-stimulating factor-differentiated human monocytes. J Immunol 2000;164:5952-60.
37. Kirsten R, Nelson K, Kirsten D, et al. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet 1998;35:9-36.
38. Chizzolini C, Chicheportiche R, Alvarez M, et al. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 2008;112:3696-703.
39. Boniface K, Bak-Jensen KS, Li Y, et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 2009;206:535-48.
40. Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A, et al. Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells. Eur J Immunol 2009;39:1301-12.
41. Kalinski P, Vieira PL, Schuitemaker JH, et al. Prostaglandin E (2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001;97:3466-9.
42. Schnurr M, Toy T, Shin A, et al. Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood 2005;105:1582-9.
43. Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10:857-63.
44. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009;119:3573-85.
45. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T (H)-17, T (H) 1 and T (H) 2 cells. Nat Immunol 2009;10:864-71.
46. Wan Q, Kozhaya L, Elhed A, et al. Cytokine signals through PI-3 kinase pathway modulate Th17 cytokine production by CCR6+ human memory T cells. J Exp Med 2011;208:1875-87.
47. Venkatachalam K, Mummidi S, Cortez DM, et al. Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2008;294:H2078-87.
48. Yoshizaki A, Yanaba K, Iwata Y, et al. Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol 185:2502-15.
49. Yoshizaki A, Yanaba K, Ogawa A, et al. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum 2011;63:3575-85.
50. Wilson MS, Madala SK, Ramalingam TR, et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010;207:535-52.
51. Nakashima T, Jinnin M, Yamane K, et al. Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012;188:3573-83.